[go: up one dir, main page]

WO2000078266A3 - Mutants d'interferon tau et leurs techniques de preparation - Google Patents

Mutants d'interferon tau et leurs techniques de preparation Download PDF

Info

Publication number
WO2000078266A3
WO2000078266A3 PCT/IB2000/001080 IB0001080W WO0078266A3 WO 2000078266 A3 WO2000078266 A3 WO 2000078266A3 IB 0001080 W IB0001080 W IB 0001080W WO 0078266 A3 WO0078266 A3 WO 0078266A3
Authority
WO
WIPO (PCT)
Prior art keywords
ifn
making
mutants
tau
directed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2000/001080
Other languages
English (en)
Other versions
WO2000078266A2 (fr
Inventor
Carol H Pontzer
Lynnette H Shorts
Christina Dancz Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland College Park
Original Assignee
University of Maryland College Park
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland College Park filed Critical University of Maryland College Park
Priority to JP2001504334A priority Critical patent/JP2003525592A/ja
Priority to AU61758/00A priority patent/AU6175800A/en
Priority to EP00948197A priority patent/EP1156771A2/fr
Priority to CA002382425A priority patent/CA2382425A1/fr
Publication of WO2000078266A2 publication Critical patent/WO2000078266A2/fr
Publication of WO2000078266A3 publication Critical patent/WO2000078266A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne le domaine de la santé humaine et animale, et plus particulièrement les usages pharmacologiques d'analogues ou de mutants de l'interféron-tau (IFN-τ) qui diffère de l'IFN-τ natif, du fait des substitutions d'acides aminés proches de la terminaison amino de la molécule d'IFN-τ qui assure une activité biologique améliorée. Les mutants d'IFN-τ décrits possèdent une faible toxicité, présentent la même activité antivirale que le très efficace IFN-alpha ou une activité légèrement réduite par rapport à celui-ci, et développent une activité antiproliférative accrue par rapport à l'activité de l'IFN-tau natif, ce qui les rend utiles pour traiter les infections virales, le cancer, et les maladies du système immunitaire notamment les maladies auto-immunes. L'invention concerne également une technique permettant de préparer de nouvelles protéines de recombinaiso, en particulier des interférons, des interleukines, des cytokines, des hormones polypeptides et d'autres produits biopharmaceutiques possédant une activité biologique améliorée sur les protéines connues, et/ou une faible toxicité, et/ou une stabilité accrue.
PCT/IB2000/001080 1999-06-22 2000-06-22 Mutants d'interferon tau et leurs techniques de preparation Ceased WO2000078266A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001504334A JP2003525592A (ja) 1999-06-22 2000-06-22 インターフェロンタウ変異体及びその製法
AU61758/00A AU6175800A (en) 1999-06-22 2000-06-22 Interferon tau mutants and methods for making them
EP00948197A EP1156771A2 (fr) 1999-06-22 2000-06-22 Mutants d'interferon tau et leurs techniques de preparation
CA002382425A CA2382425A1 (fr) 1999-06-22 2000-06-22 Mutants d'interferon tau et leurs techniques de preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14041199P 1999-06-22 1999-06-22
US60/140,411 1999-06-22

Publications (2)

Publication Number Publication Date
WO2000078266A2 WO2000078266A2 (fr) 2000-12-28
WO2000078266A3 true WO2000078266A3 (fr) 2001-08-23

Family

ID=22491109

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/001080 Ceased WO2000078266A2 (fr) 1999-06-22 2000-06-22 Mutants d'interferon tau et leurs techniques de preparation

Country Status (5)

Country Link
EP (1) EP1156771A2 (fr)
JP (1) JP2003525592A (fr)
AU (1) AU6175800A (fr)
CA (1) CA2382425A1 (fr)
WO (1) WO2000078266A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355938A2 (fr) * 2000-07-19 2003-10-29 Pepgen Corporation Composition de traitement/methode de surveillance du virus de l'hepatite c utilisant l'interferon-tau
JP2006213597A (ja) 2000-07-19 2006-08-17 Pepgen Corp インターフェロン−タウを用いるｃ型肝炎ウイルスの処置のための組成物およびモニタリングの方法
US7083782B2 (en) 2000-07-19 2006-08-01 Pepgen Corporation Method of treatment using interferon-tau
US7105154B2 (en) 2000-07-19 2006-09-12 Pepgen Corporation Method of treatment using interferon-tau
US20040126360A1 (en) * 2002-10-09 2004-07-01 Manning Mark C. Oral formulations for proteins and polypeptides
US20060134750A1 (en) * 2004-03-10 2006-06-22 Pepgen Corporation Method of treatment using interferon-tau
US20070025963A1 (en) * 2005-07-27 2007-02-01 Chih-Ping Liu Methods for reduction of scar tissue formation
WO2007098106A2 (fr) * 2006-02-17 2007-08-30 Pepgen Coporation Délivrance d'interféron-tau dans les voies respiratoires
FR2905375A1 (fr) * 2006-08-29 2008-03-07 Biomethodes Sa Variants ameliores de l'interferon alpha humain
MX2009011870A (es) 2007-05-02 2009-11-12 Ambrx Inc Polipeptidos de interferon beta modificados y usos de los mismos.
CN108840921B (zh) * 2018-05-31 2021-06-29 浙江善测禾骑士生物科技有限公司 羊α干扰素突变体及其制备方法和应用
RU2739261C1 (ru) * 2019-12-31 2020-12-22 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ количественного определения антипролиферативной активности интерферона-бета человека
WO2021216801A1 (fr) * 2020-04-22 2021-10-28 Southlake Pharmaceuticals, Inc. Interféron tau pegylé et compositions et procédés associés

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010313A2 (fr) * 1992-10-30 1994-05-11 University Of Florida Compositions d'interferon tau et leurs procedes d'utilisation
WO1997033607A1 (fr) * 1996-03-15 1997-09-18 University Of Florida Compositions d'interferon-tau administrees oralement et procedes associes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010313A2 (fr) * 1992-10-30 1994-05-11 University Of Florida Compositions d'interferon tau et leurs procedes d'utilisation
WO1997033607A1 (fr) * 1996-03-15 1997-09-18 University Of Florida Compositions d'interferon-tau administrees oralement et procedes associes

Also Published As

Publication number Publication date
EP1156771A2 (fr) 2001-11-28
JP2003525592A (ja) 2003-09-02
WO2000078266A2 (fr) 2000-12-28
AU6175800A (en) 2001-01-09
CA2382425A1 (fr) 2000-12-28

Similar Documents

Publication Publication Date Title
WO2000078266A3 (fr) Mutants d'interferon tau et leurs techniques de preparation
Rinderknecht et al. Natural human interferon-gamma. Complete amino acid sequence and determination of sites of glycosylation.
US5723121A (en) Sugar modified interferon
KR100223255B1 (ko) 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로 부터의 제조 방법
NYMAN et al. Identification of nine interferon-α subtypes produced by Sendai virus-induced human peripheral blood leucocytes
Zoon et al. Purification and characterization of multiple components of human lymphoblastoid interferon-alpha.
FI844934L (fi) Menetelmä yhdistelmägammainterferonin valmistamiseksi, jolla on parannettu stabiilisuus, ja menetelmässä käytetty vektori ja DNA
ATE402957T1 (de) Analoge des menschlichen interferon-alpha mit niedriger toxizität
NZ233974A (en) Peptide inhibitors of human leucocyte elastases, recombinant production and compositions
US7083782B2 (en) Method of treatment using interferon-tau
US5789551A (en) Human leukocyte interferon Hu-IFN-α001
US20040247565A1 (en) Method of treatment using interferon-tau
EA200000685A1 (ru) Комплекс ifnar2/ifn
WO2003016472A3 (fr) Proteines d'interferon hybride/interferon tau, compositions et procedes d'utilisation associes
WO2002086087A3 (fr) Famille proteique de cytokine
Stewart II et al. Comparisons of several biological and physicochemical properties of human leukocyte interferons produced by human leukocytes and by E. coli
CN1902224B (zh) 纯化β-干扰素的方法
MATSUDA et al. Purification and characterization of recombinant mouse interferon-β
HONDA et al. Differential purification by immunoaffinity chromatography of two carboxy-terminal portion-deleted derivatives of recombinant human interferon-γ from Escherichia coli
Tokazewski-Chen et al. Effects of nephrectomy on the pharmacokinetics of various cloned human interferons in the rat.
DIPAOLA et al. Interferon-α2 produced by normal human leukocytes is predominantly interferon-α2b
ZOON et al. Human Leukocyte-derived Alpha-Interferons: Purification and Amino-terminal–Amino-Acid Sequence of Two Components
US7780960B2 (en) Process for purifying interferon beta
Rubinstein Purification and structural analysis of interferon
WO2021233094A1 (fr) MUTANT DE L'INTERFÉRON κ ET SON PROCÉDÉ DE PRÉPARATION

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2000948197

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 61758/00

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000948197

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2382425

Country of ref document: CA

WWW Wipo information: withdrawn in national office

Ref document number: 2000948197

Country of ref document: EP